Contact
Please use this form to send email to PR contact of this press release:
ReEngage Therapeutics Announces Method of Use Patent Covering ACSS2 Inhibitors and their Use in Many Disorders
TO:
Thomas Kim
ReEngage Therapeutics Inc.
+1 215-400-0133